Please assess the completion status of the following clinical trial:

Trial Title: Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed HR+/HER2- status after MBC diagnosis.~* Received palbociclib + AI or AI as first-line therapy~Exclusion Criteria:~* Evidence of prior treatment with other CDK4/6I, AI, tamoxifen, raloxifene, toremifene, or Fulvestrant for MBC~* First structured activity greater than 90 days after MBC diagnostic date~* Treatment with a CDK4/6 inhibitor as part of a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palbociclib + an aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated Palbociclib + an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.
- Aromatase inhibitor (Type: None): Adult metastatic breast cancer patients who initiated an aromatase inhibitor as first line therapy between Feb 3, 2015 to March 31, 2020 in the Flatiron Health Analytic Database.

Based on this trial design, predict the completion outcome and termination type (if applicable).